INOVIQ Ltd (ASX:IIQ)
Australia flag Australia · Delayed Price · Currency is AUD
0.3900
+0.0050 (1.30%)
May 7, 2025, 2:28 PM AEST

INOVIQ Company Description

INOVIQ Ltd engages in the developing and commercializing of diagnostic and exosome‐based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States.

The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development.

Its cancer diagnostic pipeline includes internal and partnered diagnostic tests for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases.

The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021.

INOVIQ Ltd was founded in 2016 and is headquartered in Notting Hill, Australia.

INOVIQ Ltd
Country Australia
Founded 2016
Industry Diagnostics & Research
Sector Healthcare
Employees 15
CEO Leearne Hinch

Contact Details

Address:
23 Normanby Road
Notting Hill, 3168
Australia
Phone 61 3 9548 7586
Website inoviq.com

Stock Details

Ticker Symbol IIQ
Exchange Australian Securities Exchange
Fiscal Year July - June
Reporting Currency AUD
ISIN Number AU0000196149
SIC Code 1040

Key Executives

Name Position
Dr. Leearne Maree Hinch B.Sc., B.V.M.S., BSc., M.B.A., M.R.C.V.S. Chief Executive Officer
Mark Edwards BAcc, C.A., CA Chief Financial Officer and Company Secretary
Dr. Gregory Edward Rice BSc (Hons), GradDipMgt, MHA, Ph.D. Chief Scientific Officer
Dr. Emma Ball B.Sc., M.B.A., Ph.D. Chief Commercial Officer